Buying back VOLC on ABT's strong EPS results = good for sector.
Abbott's blowout quarter clearly shows that St. Jude's results were one-off and demand for medical products is solid. Abbott reported strong results from its vascular division as well driven by its new stent product. ABT raises its guidance as well, which adds confidence to the sector amid the uncertainty behind the healthcare bill. Look for a turnaround in VOLC shares, which found support at $15.70.